Light-Activated Compound Kills Cisplatin-Resistant Cancer
A team of international researchers has discovered a platinum-based compound which is activated by light and potent enough to kill cancers resistant to Cisplatin treatments.
Scientists from the University of Warwick, the University of Edinburgh, the University of Dundee and the Czech Republic’s Institute of Biophysics found the new compound, known as light-activated PtIV complex, is between 13 and 80 times more toxic to cancer cells than similar platinum-based drugs being used to treat cancer today.
And unlike other photodynamic therapies, this compound doesn’t require much oxygen in the cancer cell to become toxic.
The team reports their research is in the early stages, but they hope their work will lead to more efficient types of photo-activated chemotherapy which reduce the toxic side effects experienced by cancer patients. As the project’s leader explained,
“Light activation provides its massive toxic power and also allows treatment to be targeted much more accurately against cancer cells.”
Professor Peter Sadler
Chairman, Department of Chemistry
University of Warwick
If you’d like to learn more about the platinum-based compound, results from the team’s study have been published in The Proceedings of the National Academy of Science.
Source: University of Warwick News
Related Links: ScienceDaily; ecancermedicalscience; Edinburgh Research and Innovation
Related Podcast: Clinical Applications Podcast – Biomarkers of cisplatin resistance in ovarian cancer… from Proteomics
Tags: oncology; Platinol; Scotland; United Kingdom; cytotoxic
Print This
|
|
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Aetna Ends Coverage for Anesthetic Used in Colonoscopies
Previous article: Aspirin Can Halt Hormone Treatments for Prostate Cancer
